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Introduction 
 
Pursuant to 24-A M.R.S.A. §4302(5) the Superintendent of Insurance must report annually to the 
Joint Standing Committee on Insurance and Financial Services on information provided by 
carriers related to claims made for the treatment of Lyme disease and other Tick Borne illnesses. 
This report covers calendar year 2009 and contains information related to people who have 
individual health insurance policies, those covered under fully insured group health insurance 
plans, and those enrolled in the Dirigo Health Plan.  It does not include Mainecare, Medicare, 
government plans (except the State of Maine Employees Health Plan) or companies that self-
insure.  Included within the report are: the number of claims made for the treatment of Lyme 
disease and other Tick Borne illnesses; the total dollar amounts of those claims; the number of 
claim denials and reasons for those denials; the number and outcome of internal appeals; and the 
number of external appeals related to the treatment of Lyme disease and other Tick Borne 
illnesses. 
 
The Maine Center for Disease Control and Prevention has identified five kinds of reported Tick 
Borne diseases in Maine: Lyme Disease, Babesiosis, Ehrlichiosis (Anaplasmosis), Rocky 
Mountain Spotted Fever, and Powassan Virus.  Licensed health carriers are required to report to 
the Bureau of Insurance claims for all five Tick Borne illnesses.  The data include only claims 
for the treatment of tick-borne illnesses.  They do not include claims for the diagnosis of tick-
borne illnesses such as laboratory and imaging services. 
 
This data collection requirement was enacted in 2007.  The Bureau of Insurance developed an 
online report form for all licensed health carriers to enter data regarding Tick Borne disease 
treatment claims for all insured Maine residents, whether the carrier’s information is for 
enrollees in self-funded or fully insured plans.  This was the second year that Tick Borne disease 
data was collected.  A total of 435 of 443 licensed health carriers responded for a response rate 
of 98.2%.  Although this response rate is very high and provides a statistically valid sample, the 
Bureau is striving to get full compliance with the reporting requirements of the law.  Notice has 
been sent to all companies that failed to respond with data for 2009 informing them that failure 
to respond in future years will result in referral to the Legal Division. 
 
The number of claims for Tick Borne disease and the number of treatments for Lyme disease 
should not be confused with the number of actual cases of these diseases because an individual 
with these diseases can have many claims filed over the course of their treatment.  The results 
presented in Table I and Table II cannot be directly compared.  There may be several reasons for 
this including: multiple claims submitted for treatment of a single case of Lyme disease due to 
multiple office visits; companies that could not connect claims to prescriptions; and companies 
that reported office visits in Table I but were not certain whether there was Other Treatment in 
Table II.  In addition, the number of reasons for denied Tick Borne disease claims in Table III 
cannot be compared to the number of denials in Table I because there can be more than one 
reason for denial of a claim. 
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Several revisions to the reporting form will be made for next year to improve the data to be 
reported.  These revisions include: 
 
• Adding a category for pending cases, since Tables I and II of the existing form ask for 
claims submitted, claims paid and claims denied.  The number of cases submitted does 
not always equal those paid plus denied because some cases are pending; 
• Adding a new category “Single Course of Treatment over 8 Weeks” to differentiate a 
single course of treatment from multiple courses of treatment that total more than 8 
weeks; and  
• Splitting the category “Not Medically Necessary (Including 
Experimental/Investigational)” into two categories: “Not Medically Necessary” and 
“Experimental/Investigational”.    
 
Tick Borne Disease Claims by Category 
 
Table 1 shows the number of claims submitted, paid and denied by Category of Tick Borne 
disease.  The reported data include only claims made for the treatment of Tick Borne disease in 
the previous calendar year for covered individuals in Maine.  This excludes laboratory, imaging 
and other claims related to diagnosing Tick Borne diseases.  Five categories of Tick Borne 
diseases are listed based upon the International Classification of Diseases (ICD-9 codes). 
 
The figures represent the number of claims reported and not the number of enrollees with Tick 
Borne disease.  For example, one enrollee may have 10 claims within the calendar year relating 
to a diagnosis of Lyme disease.  The Percentage of Claims Paid column is calculated by dividing 
the number of claims paid by category by the number of claims submitted for that category. 
 
The company reporting the largest number of claims (10,700) indicated that they included 
presumptive diagnoses and stated that there is no way to separate presumptive diagnoses from 
patients with positive cultures. 
 
Table 1. Tick Borne Disease Claims by Category, 2009 
Total Number of Claims: 
 
 
 
Category 
Submitted Paid Denied 
Total 
Dollar 
Amount 
Paid 
Percentag
e of 
Claims 
Paid 
Lyme 14,807 12,744 2,057 $1,559,030 86%
Babesiosis 231 133 98 $49,484 58%
Ehrlichiosis (Anaplasmosis) 116 114 2 $53,630 98%
Rocky Mountain Spotted Fever 15 13 2 $3,069 87%
Powassan Virus 0 0 0 $0 --
Totals: 15,169 13,004 2,159 $1,665,213 86%
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Lyme Disease Claims by Treatment Type 
 
Table 2 shows the number of Lyme disease claims by the Type of Treatment provided for those 
claims.  The reported data include only claims made for the treatment of Tick Borne disease in 
the previous calendar year for covered individuals in Maine.  This excludes laboratory, imaging 
and other claims related to diagnosing Tick Borne diseases.  Claims for antibiotic treatment by 
any means of administration are counted.  If an enrollee submitted claims for an antibiotic 
treatment on several different occasions during the calendar year, the combined length of time 
that antibiotic was taken is used for the purpose of determining if the treatment was for 8 weeks 
or less or for more than 8 weeks.  The Other Treatment types may include non-antibiotic 
therapies administered for treatment of Lyme disease—including physical therapy, acupuncture, 
behavioral health, osteopathic manipulation, or other prescription medications.  The Percentage 
of Claims Paid column is calculated by dividing the number of claims paid by treatment type by 
the number of claims submitted for that treatment type. 
 
It is possible for information about one enrollee to be entered in more than one category.  For 
example, an enrollee could have paid claims for some antibiotics for 8 weeks or less during the 
calendar year.  That same enrollee could have a different antibiotic for 8 weeks or less be denied 
and additionally have a prescription for more than 8 weeks be paid.  The Bureau will add a new 
category “Single Course of Treatment over 8 Weeks” to the report form in order to clarify this 
issue in the future.  Therefore, it may be acceptable to enter data for the same enrollee in more 
than one place. 
 
We caution against comparing the reported data in Table 2 to the reported data in Table 1.  The 
data in Table 2 under-represents the number of Lyme disease claims by treatment type.  Based 
upon follow-up questions related to the reported data, the Bureau determined that there are 
several possible reasons why the numbers are under-represented.  These reasons include: for 
some insurance companies the data was unavailable; the insurer could not determine the 
treatment types for their members; the insurer does not collect the diagnosis at the “point of sale” 
of prescriptions or other treatment; the data could only be reported for individual cases and not 
the total number of claims; the insurer does not issue prescription coverage in Maine; or medical 
claims are stored on separate platforms from pharmacy claims and the two are not tied together.  
These discrepancies were identified when Bureau staff reviewed data from the previous year, 
and sought clarification from the insurance carriers.  After extensive interaction with several 
companies, it was determined that discrepancies exist among the companies as to what is being 
reported.  To address this and improve data for 2011,  the Bureau will be providing more 
detailed information/data request to all filing companies.  
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Table 2. Lyme Disease Claims by Treatment Type 
Total Number of Claims: 
 
Treatment Type 
Submitted Paid Denied 
Total Dollar 
Amount 
Paid 
Percent 
of Claims
Paid 
Antibiotic Treatment,  
8 weeks or less 
1,691 1,090 600 $179,089 64%
Antibiotic Treatment,  
more than 8 weeks 
204 124 80 $35,813 61%
Other Treatment 233 213 15 $36,555 91%
Totals: 2,128 1,427 695 $251,457 67%
 
Reasons for Denied Tick Borne Disease Claims 
 
Table 3 provides the reasons given for denials of payment related to any treatment for Tick 
Borne diseases.  A claim may have multiple reasons for denial.  Nearly two-thirds of the reasons 
for denial were listed as other (not among those specifically listed on the report).  More than 
1,000 of those other reasons came from one insurance carrier.  Other reasons for denial provided 
by insurance carriers include: duplicate claims; lack of referral; a mismatched membership 
number or social security number was provided; the person had other coverage and the primary 
payer paid in full; Medicare provided full coverage; the service was provided prior to effective 
date; payment was included in the allowance for another service; the provider name was missing; 
the claim was submitted to the prescription drug carrier; and a variety of reasons related to 
internal process which may have been reprocessed and approved at a later date.  Two carriers 
(who are in the same insurance group and under common control) reported that their pharmacy 
claims are on a different platform and are not tied to medical claims, so the specific reasons for 
denial were not known. 
 
 
Table 3. Reasons for Denied Tick Borne Disease Claims, 2009 
Reasons for Denial Number of  
Denied Claims 
Other Reasons for Denial 1,372
More Information Requested/Not Received 171
Coverage Terminated 170
Not a Covered Benefit 116
Not Medically Necessary (Including Experimental/Investigational) 102
Incorrect Coding  79
Non-Participating Provider  31
Maximum Benefits Exceeded  15
No Pre-Authorization  9
Pre-Existing Condition Exclusion  0
Total: 2,065
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Appeals/Reconsiderations and External Reviews for All Tick Borne Diseases 
 
Table 4 provides the number of appeals and reconsiderations that were conducted by the 
insurance companies reporting data to the Bureau of Insurance.  The Bureau had no requests for 
an independent external review relating to Lyme disease in 2009. 
 
 
Table 4. Number of Appeals/Reconsiderations and External Reviews for  
All Tick Borne Diseases, 2009 
 Upheld Overturned Total 
Appeals/Reconsideration (Internal) 5 5 10
Independent External Reviews  
(Conducted by the Insurer,  
not the Bureau of Insurance) 
0 0 0
Total: 5 5 10
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